Initial Submission DARZALEX (Cilag site)

Reg No. 1C 30/59 (NBC)

Approval date 3 Aug 2017

Variation submission

Application number	Scope	Approval date	Product Information affected	Summary
15070/62 (NB)	non-AVG	18 Jun 2019	Patient information leaflet	
15040/62 (NB)	MaV 1 Change and/or	10 May 2019	Summary of Product Characteristics	
	additional indication/dosing			
	regimen/patient			
	population/inclusion of clinical			
	information extending the			
	usage of the product			
15078/62 (NB)	non-AVG	24 Apr 2019	Patient information leaflet	
15177/61 (NB)	MiV-PA 9 Change of the test	10 Jan 2019		
	procedure of non-compendial			
	drug substance			
	MiV-N7 Withdrawal/deletion of			
	the alternative manufacturer(s)			
	(for drug substance and/or drug			
	product and/or packager)			
15172/61 (NB)	MiV-PA 2 Change of product	8 Jan 2019	Patient Information Leaflet and	
	labeling (in accordance to		Summary of Product Characteristics	

	country specific labeling			
	requirement)			
15091/61 (N)	MaV 2 Change of content of	6 Oct 2018	Patient information leaflet	
	product labeling			
15001/61 (NB)	MaV-1 Change and/or	10 Sep 2018		
	additional indication/dosing			
	regimen/patient			
	population/inclusion of clinical			
	information extending the			
	usage of the product			
15020/61 (NB)	non-AVG	10 Sep 2018		
15036/60 (NB)	MaV 15 Extension of shelf-life	28 May 2018		
	of the drug product			
	MiV-PA 10 Change of shelf-life			
	or re-test period for drug			
	substance			
	Non-AVG			